Evidence map›Paper›PMID 25732182›Full record

ArticleBrain : a journal of neurology2015

Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease.

Alaina Baker-Nigh, Shahrooz Vahedi, Elena Goetz Davis, Sandra Weintraub, Eileen H Bigio, William L Klein, Changiz Geula

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 209 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  5. Article
  6. Article
  7. The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Cognitive Impact of β-Amyloid Load in the Rapid Eye Movement Sleep Behavior Disorder-Lewy Body Disease Continuum.Movement disorders : official journal of the Movement Disorder Society · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alaina Baker-Nigh1 Cognitive Neurology and Alzheimer's Disease Centre, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Shahrooz Vahedi1 Cognitive Neurology and Alzheimer's Disease Centre, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Elena Goetz Davis1 Cognitive Neurology and Alzheimer's Disease Centre, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Sandra Weintraub1 Cognitive Neurology and Alzheimer's Disease Centre, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
Eileen H Bigio1 Cognitive Neurology and Alzheimer's Disease Centre, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
William L Klein2 Neurobiology, Northwestern University, Evanston, IL 60201, USA.
Changiz Geula1 Cognitive Neurology and Alzheimer's Disease Centre, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA c-geula@northwestern.edu.
Northwestern University · US

Funding

Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIGIO, EILEEN H. · 1996 to 2020
$28.9M
PREDOCTORAL AND POSTDOCTORAL TRAINING PROGRAM IN AGING AND DEMENTIAT32AG020506 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERT J VASSAR, SANDRA WEINTRAUB · 2002 to 2026
$9.9M
CALBINDIN AND CHOLINERGIC NEURONS IN AGING AND ADR01AG014706 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GEULA, CHANGIZ · 1999 to 2002
$830k
CaMKI, Apoptosis and Cholinergic Neurons in Aging and ADR03AG027141 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GEULA, CHANGIZ · 2006 to 2007
$139k
NIA NIH HHS AG013854NIA NIH HHS AG014706NIA NIH HHS AG027141NIA NIH HHS AG20506
6 · The paper itself

Abstract

The mechanisms that contribute to selective vulnerability of the magnocellular basal forebrain cholinergic neurons in neurodegenerative diseases, such as Alzheimer's disease, are not fully understood. Because age is the primary risk factor for Alzheimer's disease, mechanisms of interest must include age-related alterations in protein expression, cell type-specific markers and pathology. The present study explored the extent and characteristics of intraneuronal amyloid-β accumulation, particularly of the fibrillogenic 42-amino acid isoform, within basal forebrain cholinergic neurons in normal young, normal aged and Alzheimer's disease brains as a potential contributor to the selective vulnerability of these neurons using immunohistochemistry and western blot analysis. Amyloid-β1-42 immunoreactivity was observed in the entire cholinergic neuronal population regardless of age or Alzheimer's disease diagnosis. The magnitude of this accumulation as revealed by optical density measures was significantly greater than that in cortical pyramidal neurons, and magnocellular neurons in the globus pallidus did not demonstrate a similar extent of amyloid immunoreactivity. Immunoblot analysis with a panel of amyloid-β antibodies confirmed accumulation of high concentration of amyloid-β in basal forebrain early in adult life. There was no age- or Alzheimer-related alteration in total amyloid-β content within this region. In contrast, an increase in the large molecular weight soluble oligomer species was observed with a highly oligomer-specific antibody in aged and Alzheimer brains when compared with the young. Similarly, intermediate molecular weight oligomeric species displayed an increase in aged and Alzheimer brains when compared with the young using two amyloid-β42 antibodies. Compared to cortical homogenates, small molecular weight oligomeric species were lower and intermediate species were enriched in basal forebrain in ageing and Alzheimer's disease. Regional and age-related differences in accumulation were not the result of alterations in expression of the amyloid precursor protein, as confirmed by both immunostaining and western blot. Our results demonstrate that intraneuronal amyloid-β accumulation is a relatively selective trait of basal forebrain cholinergic neurons early in adult life, and increases in the prevalence of intermediate and large oligomeric assembly states are associated with both ageing and Alzheimer's disease. Selective intraneuronal amyloid-β accumulation in adult life and oligomerization during the ageing process are potential contributors to the degeneration of basal forebrain cholinergic neurons in Alzheimer's disease.

Indexed as

AdultAgedAged, 80 and overAgingAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBasal ForebrainCase-Control StudiesCerebral CortexCholinergic NeuronsFemaleGlobus PallidusHumansMaleMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorAPP protein, humanPeptide FragmentsProtein IsoformsAlzheimer pathologyamyloid oligomeramyloid-βbasal forebrain cholinergic neuronsintracellular

Identifiers

PMID25732182
PMCPMC4542619
OpenAlexW2018477409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.